Get the Stockscreener App
21.81
2.76%
-0.62
After Hours:
21.95
0.14
+0.64%
Newamsterdam Pharma Company Nv stock is traded at $21.81, with a volume of 635.51K.
It is down -2.76% in the last 24 hours and up +20.43% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$22.43
Open:
$22.43
24h Volume:
635.51K
Relative Volume:
0.77
Market Cap:
$2.45B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-10.14
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
-6.76%
1M Performance:
+20.43%
6M Performance:
-2.15%
1Y Performance:
+27.39%
1-Day Range:
$21.56
$22.88
1-Week Range:
$21.55
$24.18
52-Week Range:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
21.81 | 2.52B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
What are NewAmsterdam Pharma Company N.V. Equity Warrant company’s key revenue driversChart Pattern Updates For Fast Growth - jammulinksnews.com
Why is NewAmsterdam Pharma Company N.V. Equity Warrant stock attracting strong analyst attentionValue Investing Guidance To Watch Now - jammulinksnews.com
What is NewAmsterdam Pharma Company N.V. company’s growth strategySwing Trade Forecasts For Smart Trading - jammulinksnews.com
Does NewAmsterdam Pharma Company N.V. qualify in momentum factor screeningReal-Time Analysis With Entry Targets In Progress - metal.it
What institutional investors are buying NewAmsterdam Pharma Company N.V. stockRetirement Planning Guidance To Watch Now - jammulinksnews.com
What are analysts’ price targets for NewAmsterdam Pharma Company N.V. in the next 12 monthsFree Stock Recommendation From AI Tools - jammulinksnews.com
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Can NewAmsterdam Pharma Company N.V. recover in the next quarterDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
NewAmsterdam Pharma Company N.V. Presents Positive Data from Br Broadway Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers At Aaic 2025 - MarketScreener
Will NewAmsterdam Pharma Company N.V. Reverse From Oversold ConditionsReal-Time Trade Insights Spark Market Reactions - metal.it
NewAmsterdam Pharma Presents Positive Data from BROADWAY - GlobeNewswire
Frazier Lifesciences Acquisition : NewAmsterdam Pharma Alzheimers Analysis (1) - MarketScreener
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results - TipRanks
Breakthrough: NewAmsterdam's Obicetrapib Shows Major Alzheimer's Prevention Potential in Clinical Trial - Stock Titan
Published on: 2025-07-29 22:25:06 - metal.it
NewAmsterdam Pharma Company N.V. Equity Warrant Outperforms Peers on Volume MetricsTriple Digit Return Stock Predictions Released - metal.it
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V. Equity WarrantStock Strategy Entry Points Backed By Experts - jammulinksnews.com
What institutional investors are buying NewAmsterdam Pharma Company N.V. Equity Warrant stockExpert Picks Watchlist For 2025 - jammulinksnews.com
NewAmsterdam Pharma Company N.V. Stock Performance After Earnings: Historical InsightsInsider Level Guidance - metal.it
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V.Free Consultation - jammulinksnews.com
Why is NewAmsterdam Pharma Company N.V. stock attracting strong analyst attentionUnstoppable profit momentum - jammulinksnews.com
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyFree Daily Trading Room Entry - jammulinksnews.com
How strong is NewAmsterdam Pharma Company N.V. Equity Warrant company’s balance sheetFree Stock Market Trend Analysis - jammulinksnews.com
Should I hold or sell NewAmsterdam Pharma Company N.V. Equity Warrant stock in 2025Retirement Planning Guidance To Watch Now - jammulinksnews.com
What are NewAmsterdam Pharma Company N.V. company’s key revenue driversAchieve breakthrough financial results - jammulinksnews.com
Should I hold or sell NewAmsterdam Pharma Company N.V. stock in 2025Capitalize on stocks with high profit margins - jammulinksnews.com
What are the latest earnings results for NewAmsterdam Pharma Company N.V. Equity WarrantPhenomenal wealth increase - jammulinksnews.com
What is the dividend policy of NewAmsterdam Pharma Company N.V. stockUnlock exclusive trading strategies for gains - jammulinksnews.com
How strong is NewAmsterdam Pharma Company N.V. company’s balance sheetPhenomenal investment performance - jammulinksnews.com
What catalysts could drive NewAmsterdam Pharma Company N.V. Equity Warrant stock higher in 2025Extraordinary market timing - jammulinksnews.com
Published on: 2025-07-27 21:05:32 - jammulinksnews.com
Published on: 2025-07-27 20:54:33 - jammulinksnews.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs during market volatilityFree Predictions - Newser
What are the latest earnings results for NewAmsterdam Pharma Company N.V.Achieve rapid portfolio appreciation today - jammulinksnews.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant a Top Dividend Stock to Watch in 2025Free Stock Trading Signals - Newser
Top Risks to Consider Before Buying NewAmsterdam Pharma Company N.V. StockBreakout Level Watch - Newser
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts strong analyst attentionFree Predictions - Newser
What analysts say about NewAmsterdam Pharma Company N.V. stockRobust investment performance - PrintWeekIndia
What analysts say about NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Bull & Bear Market Updates - PrintWeekIndia
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock split in the near futureUnmatched market gains - jammulinksnews.com
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):